Private equity boardroom

Portfolio

Unlocking Hidden Value in Private Markets

We invest in lower middle-market companies with exceptional founders, applying operational expertise and patient capital to drive sustained value creation.

50+

Portfolio Companies

25%

Target IRR

Our Investment Thesis

Patient capital, partnered with exceptional management teams

01

Lower Middle Market Focus

Businesses with £5M-£50M EBITDA represent the most attractive risk-adjusted opportunity in private equity today. Less competition, more operational alpha.

02

Operational Transformation

We bring hands-on expertise in sales, technology, operations, and talent to drive fundamental business improvement beyond what capital alone achieves.

03

Patient Capital Advantage

Our flexible mandate allows 5-10+ year hold periods, compounding value without exit pressure and aligning with founder timelines.

Selected Investments

TechScale Solutions

TechScale Solutions

Enterprise Software

Partnered with founders to scale ARR from £8M to £42M through product expansion and international go-to-market strategy.

Entry Year

2019

Return Multiple

3.2x

MediCore Health

MediCore Health

Healthcare Services

Built a regional healthcare platform through three strategic acquisitions and a centralised technology infrastructure.

Entry Year

2020

Return Multiple

2.8x

GreenBuild Corp

GreenBuild Corp

Sustainable Construction

Supported management in pivoting to net-zero building methods, tripling margins and winning major government contracts.

Entry Year

2021

Return Multiple

2.1x

Investment Approach

01

Rigorous Selection

Less than 2% of reviewed opportunities reach our investment committee. Exhaustive due diligence across financials, management, and market position.

02

Active Partnership

We sit on boards, contribute operating expertise, and open our network to the businesses we back.

03

Value Creation

A structured 100-day plan and ongoing operational support to accelerate growth and unlock embedded value.

04

Disciplined Exit

Exit timing is driven by value maximisation, not fund lifecycle pressure. We are patient capital.

Their operational expertise transformed our business. They didn't just invest capital — they invested time, insight, and network.

— CEO, Portfolio Company

Access private equity returns for your portfolio.